The biggest structural limit on hair transplantation โ€” a finite donor supply โ€” is a problem scientists have worked on for decades. "Hair cloning" or "hair multiplication" aims to grow follicles in unlimited quantities in a lab.

2026 Scientific Developments

In February 2026, researchers at Japan's RIKEN Institute identified the missing third cell type required for lab-grown hair follicles โ€” PDGFRฮฑโบ CD34โบ Sca1โบ mesenchymal cells โ€” achieving 100% efficient follicle growth in lab conditions for the first time. Multiple research programs have also achieved high-throughput clonal expansion of dermal papilla cells using optimized Wnt and BMP signaling pathways.

Clinical Trial Status

The RIKEN/Organ Technologies collaboration reported that cultured dermal papilla cells produced visible hair growth in Phase I participants, with a Phase II trial enrolling roughly 200 patients across Japan beginning in late 2026. Companies like HairClone are also targeting clinical testing of cloned-cell methodologies around 2025-2026.

A Realistic Timeline

As of 2026, hair cloning is not commercially available anywhere in the world. The earliest realistic timeline for widespread access is the 2030s.

What it means today: These technologies aren't yet a treatment option. Anyone considering a transplant today should plan realistically around their current donor supply, not delay a decision in hopes that "cloning will arrive in a few years."